Lantheus Holdings (LNTH) Free Cash Flow Growth (3y) (2017 - 2026)
Lantheus Holdings (LNTH) Free Cash Flow Growth (3y) (2017 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.86 Bn | 88.00 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.96 Bn | 32.22 Bn | 1.97 Bn | 9.86% |
| 3 | Zoetis | 32.55 Bn | 30.61 Bn | 1.62 Bn | -18.92% |
| 4 | Takeda Pharmaceutical | 27.56 Bn | 23.49 Bn | 4.39 Bn | -44.64% |
| 5 | United Therapeutics | 23.05 Bn | 20.90 Bn | 648.10 Mn | 0.68% |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - | - |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | -27.74% |
| 8 | Neurocrine Biosciences | 17.75 Bn | 16.43 Bn | 800.70 Mn | 46.56% |
| 9 | Elanco Animal Health | 12.65 Bn | 12.22 Bn | 785.00 Mn | 39.19% |
| 10 | Lantheus Holdings | 6.95 Bn | 6.45 Bn | 230.92 Mn | 6.80% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.80% |
| Dec 31, 2025 | -11.94% |
| Sep 30, 2025 | -0.37% |
| Jun 30, 2025 | 10.85% |
| Mar 31, 2025 | 143.16% |
| Dec 31, 2024 | 411.15% |
| Sep 30, 2024 | 209.01% |
| Jun 30, 2024 | 30.63% |
| Mar 31, 2024 | 130.59% |
| Dec 31, 2023 | 153.41% |
| Sep 30, 2023 | 166.18% |
| Jun 30, 2023 | -114.75% |
| Mar 31, 2023 | 146.14% |
| Dec 31, 2022 | 34.74% |
| Sep 30, 2022 | 63.56% |
| Jun 30, 2022 | 57.05% |
| Mar 31, 2022 | 345.25% |
| Dec 31, 2021 | -43.96% |
| Sep 30, 2021 | -39.16% |
| Jun 30, 2021 | 20.87% |